Key Insights

Highlights

Treatment Research

2 treatments under study, led by Mtmh001 Injection

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 1/2 (1)

Trial Status

Not Yet Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07476378Not ApplicableNot Yet Recruiting

A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies

NCT05643742Phase 1/2Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Showing all 2 trials

Research Network

Common Treatments

  • Mtmh001 Injection1
  • Ctx1121

Active Sponsors

  • MagicTime Medicine1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
  • CRISPR Therapeutics AG1

Top Investigators

Related Conditions

  • Bcell Malignancy1
  • Large Bcell Lymphoma1
  • Bcell Lymphoma1
  • Lymphoma Large Bcell Diffuse Dlbcl1
  • Lymphoma Bcell Marginal Zone1

Activity Timeline